2023小明台湾永远免费区域小米

2023小明台湾永远免费区域小米

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

2023小明台湾永远免费区域小米

Learn More
Folded page of a newspaper

2023小明台湾永远免费区域小米

2023小明台湾永远免费区域小米

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

2023小明台湾永远免费区域小米

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

w加速器官网

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Newsroom
w加速器安卓

@ApellisPharma

A man with a baby in a baby carrier

2023小明台湾永远免费区域小米

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

2023小明台湾永远免费区域小米

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

2023小明台湾永远免费区域小米

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

2023小明台湾永远免费区域小米

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
w加速器app

Patricia
Quality Assurance at Apellis

佛跳墙vp最新版官方  猎豹免费加速器  王vpn  佛跳墙加器器破解版  快vipn  永远都连得上的VPN